



UNITED STATES PATENT AND TRADEMARK OFFICE

DEC - 8 2009

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 7,323,493 was filed on August 20, 2009, under 35 U.S.C. § 156. Although Applicant did not disclose (in accordance with 37 C.F.R. 1.740(a)(13)) in the attached application for patent term extension that they filed a second application for patent term extension based on the regulatory review period of New Drug Application (NDA) No. 22-245, please note that Applicant has also applied for extension of U.S. Patent No. 5,223,510 based on the same regulatory review period, i.e., NDA No. 22-245, pursuant to the provisions of 37 C.F.R. § 1.785.

The assistance of your Office is requested in confirming that the product identified in the application, MULTAQ® (dronedarone hydrochloride), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period beginning on the date the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: John D. Conway
sanofi-aventis U.S. Inc.
U.S. Patent Operations
Route #202-206/P.O. Box 6800
MAILCODE: BWD-303A
Bridgewater, NJ 08807-0800